Abstract: The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.

Abstract: An embodiment of the present invention provides a method of preparing 2,5-furandimethylcarboxylate (FDMC), including preparing 2,5-furandimethylcarboxylate (FDMC) by subjecting a reaction mixture including 5-hydroxymethylfurfural (HMF), air, and an alcohol solvent to oxidative esterification in the presence of a gold (Au)-nanoparticle-supported catalyst, in which the gold (Au)-nanoparticle-supported catalyst includes a support and gold (Au) nanoparticles supported on the support.

Abstract: A method and apparatus is disclosed that includes first and second hardware components. The first component includes at least one first input configured to receive at least one first data or power signal, at least one voltage clamping circuit configured to limit a voltage of the at least one first data or power signal, and at least one first output configured to provide the at least one voltage-limited first data or power signal. The second component includes at least one second input configured to receive at least one second data or power signal, at least one limiter circuit configured to limit an amount of energy in the at least one second data or power signal, and at least one second output configured to provide the at least one energy-limited second data or power signal.

Abstract: Technologies for enhanced network discovery and configuration include a network with a fabric manager and multiple network devices. A network device requests platform information from a management controller and receives the platform information via a sideband interface. The network device broadcasts a discovery message indicative of the platform information on a link layer network. The fabric manager discovers the network topology with an enhanced link layer discovery protocol and creates a vPOD in the network. The vPOD includes an application network with multiple racks. The fabric manager creates a tagged network domain for the vPOD. The fabric manager sends an out-of-band configuration command to the network device with a tag associated with the vPOD. After receiving the out-of-band configuration command, the network device receives a packet, compares domain metadata of the packet to the tag received from the fabric manager, and routes the packet. Other embodiments are described and claimed.

Abstract: The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: In an embodiment, a UE receives a first uplink grant for a first RAT (e.g., 5G NR) and a second uplink grant for a second RAT (e.g., LTE). In one embodiment, the UE schedules an uplink transmission on the first RAT (e.g., by selectively dropping the uplink transmission on particular resource blocks) so as to manage an amount of time that is based on concurrent uplink transmissions on both the first and second RATs are performed. In another embodiment, the UE establishes a first period of time where a BSR transmitted by the UE on the first RAT is adjusted based on scheduling of concurrent uplink multi-RAT transmissions, and a second period of time where no BSR is transmitted by the UE on the first RAT based where concurrent uplink transmissions on both the first and second RATs are not permitted to be scheduled.

Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.

Abstract: An adiabatic logic-in-memory based complementary metal-oxide-semiconductor/magnetic-tunnel-junction (ALiM CMOS/MTJ) circuit utilizes an adiabatic logic based pre-charged sense amplifier (PCSA) to recover energy from its output load capacitors. The ALiM CMOS/MTJ includes a non-volatile magnetic-tunnel-junction (MTJ) based memory. The ALiM CMOS/MTJ also includes a dual rail complementary metal-oxide-semiconductor (CMOS) logic that performs logic operations in association with the MTJ, and thereby generates logic outputs based on logic inputs. The ALiM CMOS/MTJ also includes the adiabatic PCSA, which is operatively coupled to the dual rail CMOS logic. The adiabatic logic based PCSA includes PCSA circuitry for which an input is a multi-phase power clock, and a charge recovery circuit having the output load capacitors. The charge recovery circuit is operatively coupled to the PCSA circuitry such that the ALiM CMOS/MTJ circuit uses the power clock to recover energy from the output load capacitors.

Abstract: The invention relates to an ergonomic foot pedal and to apparatuses for manual ventilation. In an embodiment, the invention provides a compact and integrated foot pedal that enables a care provider to provide positive pressure ventilation to a subject's airways and lungs, and to optionally apply suction for the purpose of aspirating mucous, secretions, meconium, blood, fluids or other such materials from a patient—specifically from airways.

Abstract: A method for minimally invasive laser ablation of a target tissue within a patient while sparing tissue within a safety zone proximate to the target tissue, comprising: guiding a laser fiber within a patient with a guidance tool; measuring a temperature within the target tissue and the safety zone based on an invasive and a non-invasive thermal sensor; computing a thermal profile in conjunction with a real-time tissue image adapted for guidance of the laser fiber with the guidance tool within the patient; and controlling a laser to deliver energy through the laser fiber, to deliver a minimally therapeutic ablation therapy to the target tissue while ensuring that the safety zone is maintained in a non-ablation condition, based on at least a treatment plan, the measured temperature, and the thermal profile.

Abstract: A computer-implemented method includes obtaining a plurality of textual records divided into clusters and a residual set of the textual records, where a machine learning (ML) clustering model has divided the plurality of textual records into the clusters based on a similarity metric. The method also includes receiving, from a client device, a particular textual record representing a query and determining, by way of the ML clustering model and based on the similarity metric, that the particular textual record does not fit into any of the clusters. The method additionally includes, in response to determining that the particular textual record does not fit into any of the clusters, adding the particular textual record to the residual set of the textual records. The method can additionally include identifying, by way of the ML clustering model, that the residual set of the textual records contains a further cluster.

Abstract: Embodiments of the present invention can simplify the use of payment cards by capturing or generating an electronic image of a customer's payment card at the time of requesting a payment card transaction, and processing the electronic image to automatically determine required payment card information, including the payment card number, account name, and expiry date printed or otherwise represented on the payment card.

Abstract: The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX® capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives.

Abstract: A system and a method for transmitting payment card information are provided. The system includes at least one memory including computer program code configured to, with at least one processor, cause the system at least to (i) receive, from a capacitive touch sensor, input signals generated in response to conductive elements of a payment card that is placed on the capacitive touch sensor, the conductive elements disposed on the payment card information present on the payment card, (ii) determine, using th e input signals, an orientation of the payment card that is placed on the capacitive touch sensor, (iii) compare the determined orientation with a reference orientation associated with the payment card, (iv) generate computer-readable payment card information based on the input signals on a condition that the determined orientation corresponds to the reference orientation, and (v) transmit the computer-readable payment card information to a payment processor module.

Abstract: Embodiments relate to hypervisors that provide hardware isolated virtualization environments (HIVEs) such as containers and virtual machines (VMs). A first HIVE includes a first virtual network interface card (NIC) and a second HIVE includes a second virtual NIC. Both virtual NICs are backed by the same physical NIC. The physical NIC has an Internet Protocol (IP) address. The virtual NICs are assigned the same IP address as the physical NIC. A networking stack of the hypervisor receives inbound packets addressed to the IP address. The networking stack steers the inbound packets to the virtual NICs according to tuples of the inbound packets. Packets emitted by the virtual NICs comprise the IP address, pass through the network stack, and are transmitted by the physical NIC with headers comprising the IP address.

Abstract: A system includes a housing having multiple slots. The system also includes multiple adaptor modules each configured to be inserted into one of the slots and perform at least one function related to an associated input or output signal. For each slot-adaptor module pair, the slot includes one of a key and a receptacle configured to receive the key, and the adaptor module includes the other of the key and the receptacle. Each key fits into the receptacle associated with one type of adaptor module and cannot fit into the receptacles associated with other types of adaptor modules. Each receptacle accepts the key associated with one type of adaptor module and cannot accept the keys associated with other types of adaptor modules. Each of at least one of the keys and the receptacles is rotatable to achieve one of multiple different orientations. Different ones of the keys have different cross-sectional shapes.